RESUMEN
BACKGROUND: Herpes simplex infections (HSV1/2) are characterized by recurrent symptoms, a risk of neonatal herpes, and the facilitation of HIV transmission. In Germany, HSV1/2 infections are not notifiable and data are scarce. A previous study found higher HSV1/2 seroprevalences in women in East Germany than in women in West Germany. We assessed changes in the HSV1/2 seroprevalences over time and investigated determinants associated with HSV1/2 seropositivity to guide prevention and control. METHODS: The study was based on the German Health Interview and Examination Survey for Adults (DEGS; 2008-2011) and the German National Health Interview and Examination Survey (GNHIES; 1997-1999). We tested serum samples from DEGS participants for HSV1 and HSV2 immunoglobulin G. We used Pearson's χ2 test to compare the HSV1/HSV2 seroprevalences in terms of sex, age, and region of residence (East/West Germany) and investigated potential determinants by calculating prevalence ratios (PR) with log-binomial regression. All statistical analyses included survey weights. RESULTS: In total, 6627 DEGS participants were tested for HSV1, and 5013 were also tested for HSV2. Overall, HSV1 seroprevalence decreased significantly from 1997-1999 (82.1%; 95%CI 80.6-83.6) to 2008-2011 (78.4%; 95%CI 77.8-79.7). In the same period, overall HSV2 seroprevalence decreased significantly from 13.3% (95%CI 11.9-14.9) to 9.6% (95%CI 8.6-10.8), notably in 18-24-year-old men (10.4 to 0%) in East Germany. Women were more likely than men to be seropositive for HSV1 (PR 1.1) or HSV2 (PR 1.6). A lower level of education, smoking, and not speaking German were associated with HSV1 in both sexes. Women of older age, who smoked, or had a history of abortion and men of older age or who had not attended a nursery school during childhood were more often seropositive for HSV2. CONCLUSION: The reduced seroprevalences of HSV1 and HSV2 leave more people susceptible to genital HSV1/2 infections. Practitioners should be aware of HSV infection as a differential diagnosis for genital ulcers. We recommend educational interventions to raise awareness of the sexual transmission route of HSV1/2, possible consequences, and prevention. Interventions should especially target pregnant women, their partners, and people at risk of HIV.
Asunto(s)
Herpes Genital/epidemiología , Herpes Simple/epidemiología , Herpesvirus Humano 1 , Herpesvirus Humano 2 , Aborto Inducido/efectos adversos , Adolescente , Adulto , Anciano , Femenino , Alemania/epidemiología , Encuestas Epidemiológicas , Herpesvirus Humano 1/inmunología , Herpesvirus Humano 1/patogenicidad , Herpesvirus Humano 2/inmunología , Herpesvirus Humano 2/patogenicidad , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad , Embarazo , Mujeres Embarazadas , Prevalencia , Estudios Seroepidemiológicos , Adulto JovenRESUMEN
BACKGROUND: In Germany, whole-cell pertussis vaccines were rapidly replaced by high-concentration acellular pertussis-containing vaccines (3+1 doses from 2 months of age) starting in 1995. Boosters were recommended for 9- to 17-year-olds (2000) and for 5- to 6-year-olds (2006). Pertussis incidence remains high despite rising vaccination coverage (VC). Therefore, we analyzed VC and vaccine effectiveness (VE) in the federal state of Brandenburg. METHODS: In a stratified case-cohort analysis, we compared VC of reported pertussis cases with VC assessed in schools and kindergartens in the following strata: Children aged 2-3 years born 2005-2009 (toddlers), 5-7 years born 1995-2006 (pre-schoolers) and 15-16 years born 1995-1996 (adolescents). We calculated VE for primary and booster vaccination using Poisson regression. RESULTS: Four-dose VE decreased from 96.9% in toddlers [95% confidence interval (CI): 72.2-99.3] to 87.8% in pre-schoolers (95% CI: 79.7-92.7) to 81.7% in adolescents (95% CI: 40.6-92.8). Four-dose VE was lower in pre-schoolers born after 1996 (75.4%) than in those born 1995-1996, ~1% and ~21% of whom had received ≥1 dose of whole-cell pertussis vaccines, respectively. VE was higher in pre-schoolers and adolescents who received a booster (92.8%and 96.5%, respectively). However, overall booster VC was only 19% and 76% in these age groups, respectively. CONCLUSIONS: We observed high VE of routine pertussis vaccination, with evidence of waning over time and improved VE after booster vaccination. Increased uptake and monitoring of recommended pertussis boosters is urgently recommended to decrease high pertussis morbidity particularly in older children and adolescents.